Johnson & Johnson vs Pfizer
Johnson & Johnson is the larger business, with $94.19bn of revenue in fiscal 2025 against $62.58bn for Pfizer (1.5 times as much). Johnson & Johnson grew faster (6.0% against -1.6%). Johnson & Johnson kept more of each dollar of sales as profit: a net margin of 28.5% against 12.4%.
| Latest fiscal year | Johnson & JohnsonJNJ, 2025 | PfizerPFE, 2025 |
|---|---|---|
| Revenue | $94.19bn | $62.58bn |
| Revenue growth | 6.0% | -1.6% |
| Net income | $26.80bn | $7.77bn |
| Operating margin | — | — |
| Net margin | 28.5% | 12.4% |
| Return on equity | 35.0% | 8.9% |
| Free cash flow | $19.70bn | $9.07bn |
| Cash | $19.71bn | $1.14bn |
| Total debt | $49.93bn | $64.80bn |
| Debt to equity | 61.2% | — |
| Dividend per share | $5.14 | $1.72 |
| Dividend yield | 1.9% | 5.5% |
| Share buybacks | $5.95bn | — |
| Employees | 138,200 | 75,000 |
| Market value | $651.18bn | $172.19bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 92 (Strong) | 78 (Strong) |
| Insider trades, 12 months | 1 buys, 36 sales | 3 buys, 2 sales |